Combination Antifungal Therapy in Treatment of Murine Pulmonary Mucormycosis: Roles of Quinolones and Azoles
- 1 July 2000
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 44 (7) , 2004-2006
- https://doi.org/10.1128/aac.44.7.2004-2006.2000
Abstract
Amphotericin B is the only recognized antifungal used in the treatment of mucormycosis. In this study, we evaluated various combinations of amphotericin B, fluconazole, and trovafloxacin or ciprofloxacin in the treatment of murine pulmonary mucormycosis. The combination of fluconazole and a quinolone has a marked effect on the outcome of murine pulmonary mucormycosis. Even though we did not optimize therapy with the drugs, these experiments suggest that azoles, especially fluconazole, in combination with either trovafloxacin or ciprofloxacin were effective in the treatment of this aggressive mycosis in the mouse model.Keywords
This publication has 6 references indexed in Scilit:
- Successful Treatment of Disseminated Mucormycosis with Liposomal Amphotericin B and Surgery in a Child with LeukemiaClinical Infectious Diseases, 1998
- Effectiveness of quinolone antibiotics in modulating the effects of antifungal drugsAntimicrobial Agents and Chemotherapy, 1997
- Rhinocerebral Mucormycosis: Evolution of the Disease and Treatment OptionsThe Laryngoscope, 1997
- Fluconazole in the treatment of three cases of mucormycosisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1995
- Rhinocerebral mucormycosis: Changing patterns of diseaseSurgical Neurology, 1994
- Treatment of murine pulmonary mucormycosis with SCH 42427, a broad-spectrum triazole antifungal drugJournal of Antimicrobial Chemotherapy, 1994